Guangzhou Bio-gene Technology Co., Ltd
Quick facts
Phase 1 pipeline
- BAFFR CAR-T · Oncology
CAR-T cell therapy targeting BAFFR - BCMA-GPRC5D CART
- BG1805
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: